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Abstract The efficacy and safety of a newly designed
Ex-PRESS X-200 drainage device for the surgical
treatment of glaucoma was evaluated. A clinical,
prospective, monocentric, non-randomised, unmasked
study on patients with medically uncontrolled glau-
coma was performed. A superficial scleral flap was
created. A posterior deep sclerectomy (DS) was
dissected without opening the Schlemm’s canal and
an Ex-PRESS X-200 device was inserted under
the scleral flap into the anterior chamber to drain
aqueous humour into the intrascleral space. Biomi-
croscopy, best-corrected visual acuity (BCVA), appla-
nation intra-ocular pressure (IOP) measurements, and
fundus examination were performed before surgery, on
the first day, the first week, and 1, 2, 3, 6, 12 and
18 months after surgery. The mean follow-up was
18.6 ± 2.4 months (mean ± SD) for the 26 eyes that
were treated with the Ex-PRESS X-200 device. Pre-
operatively, the mean BCVA was 0.6 ± 0.3, the mean
IOP was 22.0 ± 5.1 mmHg, and the mean number of
medications per patients was 2.8 ± 0.8. Eighteen
months after surgery the mean BCVA was 0.5 ± 0.4,
the mean IOP was reduced to 12.0 ± 3.9 mmHg, and
the mean number of medications per patient was
0.6 ± 1.2. Eighty-five percent of patients achieved
an IOP \ 18 mmHg with or without medication and
69% without medication. Post-operative complications
were hyphaema (15%), Seidel (15%), encysted blebs
(54%) and bleb fibrosis in 8% of patients. Mitomycin
C(MMC) was administered to 15 patients (58%) with
needling being performed on 10 (38%) of these
patients. Mid-term results of DS with the Ex-PRESS
X-200 implant demonstrated its efficacy in controlling
IOP with few post-operative complications in difficult
eyes with an increased risk of surgery failure.
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Introduction
Glaucoma is a progressive optic neuropathy charac-
terised by retinal ganglion cell loss [1]. In the case of
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drug intolerance or progression of glaucoma, despite
maximally tolerated medication, penetrating and non-
penetrating filtration surgery has become a second
step in preventing progression of ganglion cell
damage.
Trabeculectomy, first introduced in 1968, is a
widely-used penetrating filtration surgery (PFS) [2, 3].
While it is effective in controlling intra-ocular
pressure (IOP) [2, 4, 5], trabeculectomy can lead to
potentially sight-threatening complications [6, 7]. In
an attempt to lower the incidence of such complica-
tions, other techniques based on the concept of non-
perforating filtration surgery (NPFS), were developed.
Compared to trabeculectomy NPFS offers the advan-
tage of lowering the complication rate with compa-
rable efficiency in controlling IOP [8–10]. Despite
promising results, deep sclerectomy with collagen
implant (DSCI) presents the relative disadvantage of
being a difficult technique to perform [11–14].
To simplify trabeculectomy, the Ex-PRESS tube
was developed in the late 1990s. It is a miniature,
unvalved, stainless steel drainage device designed to
offer fast, simple and safe glaucoma surgery [15–17].
The Ex-PRESS R-50 (indicating 50 lm lumen) was
initially inserted under a conjunctival flap [18, 19];
however, due to post-operative complications new
implantation techniques have now been developed
[20–23].
To simplify the difficult dissection during deep
sclerectomy (DS) and to keep the advantage of the
alternative aqueous humour outflow (intrascleral bleb,
subchoroidal filtration) a modified DS using the
Ex-PRESS X-200 (200 lm lumen) was developed.
The purpose of this study is to report on mid-term
results in controlling IOP and the rate of complica-
tions when using this device and implantation tech-
nique in medically uncontrolled glaucoma.
Patients and methods
Twenty-six eyes of 26 patients with medically uncon-
trolled glaucoma and/or refractory glaucoma under-
went a modified DS with the Ex-PRESS X-200 device.
The surgery was performed by one ophthalmic surgeon
(AM) at the Jules Gonin Eyes Hospital in Lausanne,
Switzerland. This prospective, monocentric, non-ran-
domised, unmasked study was approved by the Ethics
Committee of the University of Lausanne. The patients
gave their informed consent for the conduction of this
study.
The patients selected for this study suffered from
glaucoma defined as either an IOP [ 21 mmHg
despite maximally tolerable glaucoma therapy and/
or evidence of progression of visual field defects and/
or optic nerve cupping progression. Patients were
excluded if they suffered from neovascular, or con-
genital glaucoma, if they underwent previous eye
surgery \ 6 months before enrolment in this study,
or if they required combined surgery due to lens
opacities.
Ophthalmic examinations were performed before
surgery, on the first day, first week, and one, two,
three, six, 12 and 18 months after surgery. They
consisted of measurement of the best-corrected visual
acuity (BCVA) on a 6 m Snellen chart, IOP with a
Haag-Streit Goldmann applanation tonometer,
slit-lamp biomicroscopy, gonioscopy and fundus
examination including the vertical cup/disc ratio
evaluation. Visual fields were performed with the
Octopus 123 and glaucoma medications were col-
lected. At each post-operative examination, the bleb
status, anterior chamber (AC) depth, presence of cells
and degree of flare in the AC, and position of the tube
under gonioscopy were assessed.
All operations were performed under retrobulbar
anaesthesia, apart from two patients who underwent
general anaesthesia. The conjunctiva and Tenon’s
capsule were opened at the limbus. A 5 9 4 mm
limbus-based superficial scleral flap, 300 lm thick,
was dissected using a crescent ruby knife (Fig. 1a). A
0.2 mg/ml mitomycin C(MMC) (0.02%) solution was
administered with a sponge under the scleral flap and
under the conjunctival flap for 30–60 s in patients
with risk factors for subsequent fibrosis. Changes
from the conventional DS consisted of dissecting a
rectangle of deep sclera (4 9 290.5 mm) in the
posterior part of the scleral bed, behind the Schlemm’s
canal, without opening it (Fig. 1b). A paracentesis
was then performed with a 21 G needle, about 1 mm
behind the blue-white zone transition (Fig. 1c). The
Ex-PRESS implant was inserted through the paracen-
thesis into the AC allowing aqueous humour to flow
into the intrascleral space (Fig. 1d). The AC was then
filled with low-molecular-weight visco-elastic to keep
the AC depth and to create a resistance for the aque-
ous humour outflow. The superficial scleral flap was
repositioned over the implant and closed using two
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10–0 nylon sutures (Fig. 1e). The conjunctiva and
Tenon’s layer were closed with two running 8–0
resorbable sutures.
This new Ex-PRESS X-200 model (Optonol Ltd,
Neve Ilan, Israel) is an improved version of the
Ex-PRESS R-50 and is designed to improve the
subscleral filtration of aqueous humour and to decrease
the risk of tube obstruction. This unvalved tube
measures 1.5 mm in length, 650 lm external diam-
eter and 200 lm lumen diameter. It presents the
following features: (1) the distal end is rounded to
avoid microtrauma to the iris, (2) the orifice draining
the aqueous humour is located on the opposite side of
the iris plane to avoid incarceration with the iris
stroma, (3) a spur located at the distal part prevents
extrusion of the tube, and (4) a slit flange at the
proximal end prevents excessive penetration upon
insertion (Fig. 2). Biocompatibility of the stainless
steel was demonstrated in a histological study [16].
Complications were defined as follows: hyphaema,
when C1 mm blood was present in the AC; hypotony,
when post-operative IOP was B6 mmHg for more
than 2 weeks; shallow AC when there was an
iridocorneal touch in the periphery; Seidel sign, when
aqueous humour was seen leaking from the bleb using
fluorescein; and encysted (bleb elevation) or fibrosis
(flat scarring) of the filtering bleb with a resulting
increase in IOP. When the filtering blebs were
encapsulated, subconjunctival injections of 0.02%
MMC solution were administered. Needling was
performed in the case of an encysted bleb.
Surgery was considered a complete success when
the IOP without medication was [6 mmHg and
B18 mmHg. Qualified success used the same criteria
Fig. 1 a Fornix-based
conjunctival access in the
upper quadrant. A
5 9 5 mm, 300 lm thick
limbus-based superficial
scleral flap is performed.
b Dissection of deep scleral
flap (3 9 4.5 mm) in the
posterior part of the scleral
bed without opening
Schlemm’s canal.
c Paracenthesis with a 21 G
needle anterior to the deep
sclerectomy about 1 mm
behind the blue-white zone.
d Insertion of the
Ex-PRESS X-200 implant
through the 21 G
paracenthesis into the
anterior chamber. e The
superficial scleral flap is
secured using two single
nylon sutures
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with or without medication. Failure occurred when
the IOP was [18 mmHg, and/or further glaucoma
surgery was required, or the implant was removed.
Post-operative bleb management and encapsulation
modulation using the needling technique, with or
without MMC injection, were not criteria for failure.
Data are expressed as mean ± SD. Results were
analysed using Student t-test (IOP), the Wilcoxon
signed-rank test (BCVA, number of medication) and
Kaplan–Meier survival curves. Differences were con-
sidered significant when P \ 0.05. With a n-value of
26 we have at least 90% power to detect differences in
IOP before and after surgery of at least 3 mmHg with
a SD of 3 mmHg at a two-sided alpha level of 0.05.
Results
The Ex-PRESS X-200 implant was introduced into
26 eyes of 26 patients between 29 September 2005
and 30 January 2006. The mean follow-up period was
18.6 ± 2.4 months. The mean age of the patients at
the time of surgery was 74.9 ± 10.9 years (mean ±
SD), 10 were male (38.5%) and 16 female (61.5%)
(see Table 1 for demographics). Pre-operative diag-
noses are presented in Table 1. Of the 26 patients, 20
(76.9%) had previous failed glaucoma surgery that
included laser iridotomy, iridoplasty or classic filter-
ing procedure.
The IOP decreased from a mean pre-operative
pressure of 22.0 ± 5.1 mmHg to a mean IOP of 4.8 ±
5.4 mmHg (78.2% reduction) at 1 week, 12.0 ± 6.3
mmHg (45.5% reduction) at 1 month, 12.7 ± 3.8 mmHg
(42.7% reduction) at 2 months, 12.1 ± 5.0 mmHg
(45% reduction) at 3 months, 12.0 ± 4.6 mmHg (45.5%
reduction) at 6 months, 11.8 ± 3.8 mmHg (46.4% reduc-
tion) at 12 months, and 12.0 ± 3.9 mmHg (45.5%
reduction) at 18 months (Fig. 3).
The BCVA measurement changed from a mean
pre-operative value of 0.6 ± 0.3 to 0.5 ± 0.4 at the
last visit.
The reduction in anti-glaucomatous medication
after the surgery was significant. Eighteen months
after surgery the mean number of medications per
patient was reduced from a pre-operative value of
Fig. 2 a Schematic
representation of the newly
designed Ex-PRESS X-200
tube. b Schematic drawing
of the aqueous drainage
mechanism with the
Ex-PRESS X-200 implant
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2.8 ± 0.8 to 0.6 ± 1.2, showing a reduction of 79%
(P \ 0.001). Fifteen patients (58%) required subcon-
junctival MMC injections to treat bleb encapsulation.
The mean number of injections per patient was 1.5 ±
1.8 and the mean time between surgery and MMC
injection was 43.9 ± 37.4 days. Ten (38%) of these 15
patients underwent needling to treat encysted blebs.
Table 2 shows the post-operative complications.
At the end of the follow-up, the cumulative
success rates based on Kaplan–Meier were 69% for
complete success and 85% for qualified success,
respectively. Failure occurred in one patient (3.8%);
however, this patient was successfully re-operated.
Discussion
The use of glaucoma drainage devices (GDDs) as a
filtering procedure was first reported in 1907 [3]. They
are generally used for the treatment of complicated
cases after the failure of other surgical approaches
[15].
Glaucoma surgery with a miniature drainage
device was introduced in the late 1990s [15–19].
The initial tube design, the Ex-PRESS R-50, was
Table 1 Demographics
Demographics Results
Number of patients 26
Mean age (years ± SD) 74.9 ± 10.9
Male/female 10/16
White/black 26/0
Pre-operative IOP (mmHg ± SD) 22.0 ± 5.1
Pre-operative vC/D (mean ± SD) 0.9 ± 0.1
Pre-operative number of glaucoma
medication per patient (mean ± SD)
2.8 ± 0.8
Follow-up (months ± SD) 18.6 ± 2.4
Type of glaucoma Number
of patients
Primary open-angle glaucoma 8 (30%)
Pseudo-exfoliative glaucoma 7 (27%)
Pseudophakic glaucoma 4 (15%)
Normal tension glaucoma 2 (8%)
Uveitic glaucoma 2 (8%)
Traumatic glaucoma 1 (4%)
Primary angle-closure glaucoma 1 (4%)
Glaucoma secondary to ciliar and iris
melanoma with radiotherapy
1 (4%)
18
6
0
5
10
15
20
25
30
35
40
0 5 10 15 20 25 30 35 40
Preop Mean IOP mmHg
Fi
na
l M
ea
n 
IO
P 
m
m
Hg 20% IOP reduction
Fig. 3 Scattered graph of
the mean preoperative and
last control IOP
measurements (P \ 0.05)
Table 2 Post-operative complications
Post-operative complications Number of patients
Transient hypotony 4 (15%)
Hyphaema 4 (15%)
Seidel 4 (15%)
Shallow anterior chamber 2 (8%)
Encysted blebs 14 (54%)
Blebs fibrosis 2 (8%)
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intended to replace trabeculectomy and was designed
for subconjunctival implantation [16–19]. In a three-
year follow-up study by Traverso et al. [18] of 26
eyes implanted with this device, the overall success
rate with an IOP B 21 mmHg at the last visit with or
without medications was 76.9%. Other studies reported
similar success rates but also significant rates of
complications including conjunctival erosion, tube
obstruction and device dislocation. In the major-
ity of these complications, the device had to be
removed [20, 21, 24, 25].
Based on the initial results, new ideas have led to
the design of alternative implantation techniques for
the device and the development of a new generation of
Ex-PRESS drainage devices. The rational for an
improved method was that the superficial scleral flap
created by trabeculectomy or DS, might serve as a
protection to prevent the above-mentioned complica-
tions [22, 23, 26]. The Ex-PRESS R-50 device was
found to be safe and effective when implanted under a
scleral flap, as reported by Dahan and Carmichael
[22]. In a retrospective clinical study on 100 eyes,
Maris et al. reported a similar IOP-lowering efficacy
using the Ex-PRESS R-50 implant under a scleral flap
with a lower rate of early hypotony when compared
with trabeculectomy 11 months after surgery [23].
Coupin found similar satisfactory results after implan-
tation of this device under a scleral flap in open-angle
glaucoma patients [26].
The Ex-PRESS X-200 was designed to improve
the subscleral filtration of the aqueous humour. The
tip of the inner portion of the tube is rounded to
prevent impalement of the iris stroma on the tube.
The outer portion of the device is composed of a plate
that incorporates a ridge to prevent the scleral flap
from obstructing the port outlet. All these improve-
ments in the design have resulted in satisfactory
outcomes. In this study the qualified success rate
18 months after surgery was 85%. This rate com-
pared favourably with results for trabeculectomy or
DSCI [10–14].
None of the complications (tube obstruction and
conjunctival erosion) were observed with the Ex-PRESS
X-200 under a scleral flap and partial DS. Similar
results were reported by several groups also using the
implant under a scleral flap [22, 23, 26].
The second aim of this study was to report on
the results of the modified DS. DS was developed in
the 1990s in an attempt to reduce the number of
post-operative complications of glaucoma surgery [2,
9–14]. Despite good long-term post-operative results,
non-penetrating glaucoma surgery requires a high
degree of surgical skill. Most of the complications are
related to the learning phase [10–14].
After the modified DS, aqueous humour is drained
through the subconjunctival space, the intrascleral
space (via newly-grown drainage channels), and the
subchoroidal space. The surgical technique is greatly
simplified in comparison with the non-penetrating
procedure and consists essentially of creating a scleral
flap, as for a trabeculectomy, and performing a mini-
mally invasive penetrating procedure. The DS is
limited to 1–2 mm behind the Schlemm’s canal, thus
avoiding the delicate dissection of both the canal
and the fragile trabeculo-Descemet’s membrane. The
implantation of the tube in the scleral space is
straightforward. Suturing of the scleral flap is not
watertight, so an external filtration and bleb formation
were the primary goals/results of this technique.
The mean pre-operative IOP with medication was
not elevated (22 ± 5.1 mmHg) and surgery was
performed in an attempt to lower the need for anti-
glaucoma medication as well as to prevent further
progression of the optic nerve cupping, which was
associated with deterioration of the visual field
sensitivity. The mean BCVA decreased during the
18 month follow-up period for most patients. Five of
them suffered a marked reduction in their visual
acuity due to progression of retinal diseases (age-
related macular degeneration and diabetic retinopa-
thy) not related to the glaucoma surgery.
The main post-operative complications reported in
our study were encapsulation of the bleb which was
present in about half of the patients with 40% requiring
further bleb management and bleb needling with anti-
metabolic injections. We can hypothesise about the
aetiology of this scarring response. The possible role
of some inflammatory mediators present in the aque-
ous humour may have triggered a late tissue remod-
elling response in such sensitive eyes. For instance a
case of significant encapsulation was found in a patient
with a history of herpetic kerato-uveitis and posterior
capsular opacification treated with a Nd:YAG capsu-
lotomy. A second patient at risk for failure had a
complicated phaco-emulsification with capsular bag
rupture and AC implantation. A third patient under-
went an extra-capsular cataract extraction. We had
two more cases with narrow-angle configuration and
666 Int Ophthalmol (2010) 30:661–668
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elevated post-operative IOP, a situation which limits
the indication of Ex-PRESS tubes in such eyes.
The limitations of this study are related to the
relatively small number (27) of patients included,
although this figure is comparable to that reported in
the literature [18, 22, 24]. The tube was visible on
slit-lamp biomicroscopy during the post-operative
controls and this could have led to some unavoidable
bias in the interpretation of the results and compli-
cations. The study was, for this reason, a non-masked
design. The patients were enrolled in the study in a
non-randomised and non-consecutive sequence and
this could have also contributed, to a lesser degree, to
some bias analysis for the observers. The investiga-
tors tried their best to minimise the influence of these
factors in their analysis of the results and complica-
tions. The strength of this study lies in the prospective
investigation of a standardised surgical technique
performed by the same surgeon.
To conclude the Ex-PRESS X-200 tube implanted
under a scleral flap prevents the previous complica-
tions reported in the implantation under the conjunc-
tiva. The IOP was well controlled with few transient
complications. The new surgical technique, combin-
ing the placement of a large-lumen Ex-PRESS tube
with the preparation of a deep intrascleral filtration
bed can increase the efficacy and safety of filtering
surgery in complicated eyes with a high risk of failure.
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